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ber 2009 using SDI’s VONA and VOPA databases. Statistical analyses were performed 
using one-way ANOVA; signiﬁcant results had p < 0.05. RESULTS: Although indi-
viduals ages 55–64 did not dominate the NPRx—ranging from 15% to 26%—this 
group was the second-largest contributor to all prescriptions (TRx) for all the drug 
markets, ranging from 20% to 30%. The average size of prescriptions for this age 
range was statistically equivalent to the average size for the ≥65 population, indicating 
that prescriptions were reﬁlled equally frequently in both populations. Medicare 
beneﬁciaries paid signiﬁcantly less, on average, for drugs in the ﬁve classes compared 
to others by a margin of 20% to 93%. CONCLUSIONS: Individuals approaching 
Medicare eligibility are a demographic with signiﬁcant demand for coverage. They 
show consistently high drug demand; prescription sizes are equal to patients over 65 
and costs signiﬁcantly higher Medicare patients, resulting in a great expenditure for 
covering this population. From the consumer perspective, it is important to recognize 
that the combination of higher OPC and high prescription demand creates a signiﬁcant 
cost burden.
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OBJECTIVES: To assess trends in the utilization and cost of the six protected medica-
tion classes in the Part D program between calendar years 2006 and 2007. METHODS: 
The primary data sources were the prescription drug event data in the Chronic Condi-
tion Warehouse (CCW) matched to the Beneﬁciary Annual Summary for 2006 and 
2007. Data were inﬂation-adjusted for 2007 costs. Results are based on analysis of 
100% data for Medicare beneﬁciaries in the CCW. The six protected medication 
classes under study were anticonvulsants, antidepressants, antineoplastics, antipsy-
chotics, antiretrovirals, and immunosuppressants. RESULTS: Immunosuppressants 
were utilized by the fewest number of beneﬁciaries for 2006 and 2007 (81,974 and 
80,187, respectively); antidepressants were utilized the most (6,040,698 and 
6,645,639, respectively). Immunosuppressants had the lowest aggregate ingredient 
costs for both years ($204 million and $199 million, respectively). Antipsychotics had 
the highest ($4,161 million and 4,807 million, respectively). Ingredient costs to total 
Medicare expenditures ranged from 4.2% for antidepressants to 25.2% for antiretro-
virals in 2006. Results were similar for 2007 (4.5% for antidepressants to 29.4% for 
antiretrovirals). From 2006 to 2007, antidepressants had the lowest increase and 
antiretrovirals the highest. Regarding ingredient cost payment per beneﬁciary, antiret-
rovirals had the highest increase from 2006 to 2007 at 17.6% while immunosuppres-
sants decreased by −0.2%. CONCLUSIONS: Between 2006 and 2007, beneﬁciary 
utilization based on number of users per protected class increased for all classes except 
for immunosuppressants. Aggregate ingredient cost payments increased for all six 
protected classes. Based on ingredient cost payments per beneﬁciary, the immunosup-
pressant class was the only protected class showing a slight decrease; all other classes 
showed an increase.
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OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospi-
tals were encouraged to make their own incomes with the aim of mobilizing medical 
workers and improving hospital efﬁciency. Less government funding resulted in 
deﬁcits for public health institutions, which forced hospitals to generate their own 
revenue by aggressively selling drugs, especially antibiotics. To stem the tide of rising 
public complaints about high medical costs, the NDRC has capped the cost of hun-
dreds of drugs over the years. However, critics argue the price cuts have not been the 
cure since drug manufacturers often change the name and packaging of their drugs to 
escape price controls. Some hospitals and clinics have also turned a blind eye to 
government price caps and refuse to prescribe lower priced alternative drugs. This 
study was designed to evaluate the impact of inappropriate antibiotic use on inpa-
tients’ cost during the hospital stay. METHODS: One thousand cases with antibiotic 
treatment from 10 hospitals of 5 provinces in China in 2005. We created multivariate 
linear regression model for hospital cost and logistic regression model for rationality 
evaluation of antibiotic use. RESULTS: We collected 964 valid cases. Rate of inap-
propriate antibiotic use was 58.4%. Costs of inpatients with inappropriate antibiotic 
use was as 2.75 times as the ones with appropriate use (P < 0.001). Risk factors 
included antibiotic prophylaxis (OR = 2.929), operations (OR = 2.44), long hospital 
stay (OR = 1.021 for every prolonged day) and regional factors. Protection factor was 
in tertiary hospital (OR = 0.510). CONCLUSIONS: Inappropriate antibiotic use 
contributes to inpatients’ high cost. Efforts to control misuse of antibiotic should be 
pursued.
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OBJECTIVES: To study the trends in emergency department (ED) visits due to opioid 
abuse from 1996 to 2007 in United States. METHODS: ED visits attributable to 
opioid abuse were identiﬁed using diagnosis codes (ICD-9-CM codes: 304.0, 304.7, 
305.5 and 965.0) from the National Hospital Ambulatory Medical Care Survey. 
Annual rate of ED visits for opioid abuse per 1000 people was estimated. To increase 
estimation precision, data from two consecutive years were pooled. Bivariate analysis 
and logistic regression were performed to examine the associations of patient demo-
graphic characteristics to ED visits for opioid abuse. Data were analyzed using STATA 
9.2 accounting for complex survey design. RESULTS: Of the total 1,289,529,680 
estimated ED visits made during the 12-year period, 1,633,224 (0.13%) were attribut-
able to opioid abuse. ED visits for opioid abuse increased from 70,748 visits per year 
(0.08%) in 1996–1997 to 208,378 (0.18%) in 2006–2007. The annual rate of ED 
visit for opioid abuse per 1000 people increased from 0.26 in 1996–1997 to 0.70 in 
2006–2007, with an estimated 8% annual increase (p < 0.001). Children and elderly 
were less likely to have an ED visit for opioid abuse compared to nonelderly adults 
aged 34–64(AOR 0.075, 95% CI 0.042–0.134; AOR 0.067, 95% CI 0.026–0.173 
respectively). Females were less likely to have an ED visit for opioid abuse than males 
(AOR 0.555, 95% CI 0.443–0.695).Compared to the West, people in the South and 
Midwest were less likely to have an ED visit for opioid abuse (AOR 0.447, 95% CI 
0.313–0.638; AOR 0.517, 95% CI 0.334–0.799 respectively). Risks of ED visits for 
opioid abuse more than doubled in years 2002–2003 and 2006–2007 (AOR 2.286, 
95% CI 1.420–3.679; AOR 2.329, 95% CI 1.473–3.682 respectively) compared to 
1996–1997. CONCLUSIONS: The number and rate of ED visits for opioid abuse 
increased over time with the highest in 2006–2007.
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OBJECTIVES: To assess and describe episodes of care and inpatient mortality follow-
ing poisonings from over-the-counter (OTC) medications that resulted in hospital 
inpatient admissions in the United States from 2002–2006. METHODS: This retro-
spective study used the nationally-representative sample of hospital discharge records 
from the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost 
Utilization Project (HCUP) Nationwide Inpatient Sample. Cases with any ICD-9 
diagnoses related to poisoning from OTC medications (e.g., codes 965.4, E850.3, 
E945.4) were included for analysis. Descriptive approaches and logistic regression 
were used to assess patient and hospital characteristics, costs, patterns of care and 
utilization, potential disparities of care, and inpatient mortality rates. RESULTS: A 
total of 360,636 inpatient admissions associated with poisonings from OTC medica-
tions occurred from 2002 through 2006. Cases averaged 43.4 ± 20.0 years of age, 3.5 
± 4.6 days length of stay, and $14,808 ± 24,868 in charges. Further, 1.3% of cases 
resulted in patient mortality, which averaged 55.3 ± 19.5 years of age, 5.7 ± 9.1 days 
length of stay, and $44,904 ± 64,738 in charges. The national bill associated with 
OTC poisonings totaled $5.25 billion across the 5 years. Increased odds of inpatient 
mortality were associated (p ≤ 0.05) with patient age, total charges, number of comor-
bidities, patients who self-pay, the regional location of hospitals in the United States, 
and increased case-mix severities. Conversely, decreased odds of inpatient mortality 
were associated (p ≤ 0.05) with shorter lengths of stay, bed-sizes of hospitals, hospitals 
in urban settings, and teaching hospitals. CONCLUSIONS: Inpatient hospitalizations 
associated with poisonings from OTC medications accounts for a substantial burden 
of illness often exceeding 50,000 cases per year and summing to $5.25 billion over 
ﬁve years. Despite a small percentage of inpatient mortality, further research is needed 
on the costs and outcomes following discharge, as well as those treated and released 
solely in emergency departments, and OTC poisonings among children.
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OBJECTIVES: To examines the presence of spatial clusters across states in total 
number of prescription drugs ﬁlled at retail pharmacies in US METHODS: Using data 
on total number of prescription drugs ﬁlled at retail pharmacies by each state in US 
from Vector One and National by Verispan, L.L.C in 2008, Moran’s I statistic for 
global spatial dependence (i.e. cluster) was used to identify if clusters existed. In 
Moran’s I, weight matrix to deﬁne neighbors was utilized using Rook 1st order contigu-
ity weight, Queen 1st order contiguity and 4-nearest neighbors. Permutations using 
999 repetitions was used to calculate p-values in each weight matrix. RESULTS: 
Signiﬁcant positive global spatial autocorrelation in total number of prescription drugs 
ﬁlled at retail pharmacies was found regardless of any weight matrix. Moran’s I using 
Rook weight was 0.259 and p-value was 0.003. Moran’s I using Queen weight and 
4-nearest neighbors were 0.263 (p-value = 0.002) and 0.412 (p-value = 0.001), respec-
tively. CONCLUSIONS: Findings showed that clusters or non-randomness in total 
number of prescription drugs ﬁlled at retail pharmacies existed. Non-randomness 
implies two things. In statistical analysis, this cluster effect should be considered. And, 
policy makers should consider clusters when they make a decision for health care 
distributions.
